Patents by Inventor Cristina Basilico
Cristina Basilico has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11814433Abstract: An anti-HGFR antibody fragment in combination with an extracellular portion of human HGFR for use in the treatment of a patient suffering from a tumor and/or metastasis, wherein: (i) the anti-HGFR antibody fragment has only one paratope able to bind to an epitope of the extracellular portion of human HGFR and has antagonist activity towards HGFR, (ii) the extracellular portion of human HGFR is capable of binding to HGF in a stable manner and contains at least one amino acid mutation at the epitope recognized by the anti-HGFR antibody fragment to prevent binding of the anti-HGFR antibody fragment thereto, and (iii) the anti-HGFR antibody fragment and the extracellular portion of human HGFR are suitable for administration to the patient are suitable for administration to the patient (a) in a protein form or (b) in a nucleic acid form.Type: GrantFiled: March 21, 2019Date of Patent: November 14, 2023Assignee: Vertical Bio AGInventors: Cristina Basilico, Elisa Vigna, Paolo Maria Comoglio
-
Publication number: 20210395372Abstract: An anti-Met antibody fragment comprising a single antigen binding arm and an Fc region, wherein the antigen binding arm is defined by the variable regions having amino acid sequences as set forth in SEQ ID No.: 7, 8 and wherein the anti-Met antibody fragment is useful in the treatment of a tumor and/or metastasis.Type: ApplicationFiled: October 7, 2019Publication date: December 23, 2021Inventors: Elisa VIGNA, Cristina BASILICO, Tiziana CREPALDI, Paolo Maria COMOGLIO
-
Publication number: 20210070868Abstract: An anti-HGFR antibody fragment in combination with an extracellular portion of human HGFR for use in the treatment of a patient suffering from a tumor and/or metastasis, wherein: (i) the anti-HGFR antibody fragment has only one paratope able to bind to an epitope of the extracellular portion of human HGFR and has antagonist activity towards HGFR, (ii) the extracellular portion of human HGFR is capable of binding to HGF in a stable manner and contains at least one amino acid mutation at the epitope recognized by the anti-HGFR antibody fragment to prevent binding of the anti-HGFR antibody fragment thereto, and (iii) the anti-HGFR antibody fragment and the extracellular portion of human HGFR are suitable for administration to the patient are suitable for administration to the patient (a) in a protein form or (b) in a nucleic acid form.Type: ApplicationFiled: March 21, 2019Publication date: March 11, 2021Inventors: Cristina BASILICO, Elisa VIGNA, Paolo Maria COMOGLIO
-
Patent number: 10676535Abstract: The present invention relates to antibodies that specifically bind to the human c-Met receptor protein and that act as strict antagonists of hepatocyte growth factor (HGF)-mediated activation of the c-Met receptor and also inhibit HGF-independent activation of the human c-Met protein.Type: GrantFiled: December 26, 2017Date of Patent: June 9, 2020Assignee: argenx BVBAInventors: Anna Hultberg, Michael Saunders, Johannes De Haard, Els Festjens, Natalie De Jonge, Paolo Michieli, Cristina Basilico, Torsten Dreier
-
Publication number: 20180215833Abstract: The present invention relates to antibodies that specifically bind to the human c-Met receptor protein and that act as strict antagonists of hepatocyte growth factor (HGF)-mediated activation of the c-Met receptor and also inhibit HGF-independent activation of the human c-Met protein.Type: ApplicationFiled: December 26, 2017Publication date: August 2, 2018Inventors: Anna HULTBERG, Michael SAUNDERS, Johannes DE HAARD, Els FESTJENS, Natalie DE JONGE, Paolo MICHIELI, Cristina Basilico, Torsten DREIER
-
Patent number: 9884917Abstract: The present invention relates to antibodies that specifically bind to the human c-Met receptor protein and that act as strict antagonists of hepatocyte growth factor (HGF)-mediated activation of the c-Met receptor and also inhibit HGF-independent activation of the human c-Met protein.Type: GrantFiled: December 6, 2013Date of Patent: February 6, 2018Assignee: ARGEN-X N.V.Inventors: Anna Hultberg, Michael Saunders, Johannes De Haard, Els Festjens, Natalie De Jonge, Paolo Michieli, Cristina Basilico, Torsten Dreier
-
Patent number: 9688773Abstract: The invention provides a product combination or composition, and also multispecific antibodies comprising two or more antigen-binding sites (as antibodies or antigen binding fragments thereof), wherein two the antigen-binding bind to distinct non-overlapping epitopes of the human c-Met protein. The product combination or composition or multispecific antibody inhibits HGF-independent activation of the human c-Met receptor protein.Type: GrantFiled: November 3, 2011Date of Patent: June 27, 2017Assignee: ARGEN-X N.V.Inventors: Anna Hultberg, Michael Saunders, Johannes De Haard, Els Festjens, Natalie De Jonge, Paolo Michieli, Cristina Basilico, Torsten Dreier
-
Patent number: 9310377Abstract: Use of a polynucleotide encoding or a polypeptide comprising at least the extra-cellular IPT-3 and IPT-4 domains of hepatocyte growth factor receptor for the screening and/or development of pharmacologically active agents useful in the treatment of cancer, preferably a cancer with dysregulation of hepatocyte growth factor receptor.Type: GrantFiled: February 21, 2013Date of Patent: April 12, 2016Assignee: METHERESIS TRANSLATIONAL RESEARCH SAInventors: Paolo Maria Comoglio, Paolo Carminati, Paolo Michieli, Cristina Basilico
-
Patent number: 9121854Abstract: Use of a polynucleotide encoding or a polypeptide comprising at least the extra-cellular IPT-3 and IPT-4 domains of hepatocyte growth factor receptor for the screening and/or development of pharmacologically active agents useful in the treatment of cancer, preferably a cancer with dysregulation of hepatocyte growth factor receptor.Type: GrantFiled: August 31, 2011Date of Patent: September 1, 2015Assignee: METHERESIS TRANSLATIONAL RESEARCH S.A.Inventors: Cristina Basilico, Paolo Michieli, Paolo Carminati, Paolo Maria Comoglio
-
Patent number: 8637027Abstract: The present invention relates to antibodies that specifically bind to the human c-Met receptor protein and that act as strict antagonists of hepatocyte growth factor (HGF)-mediated activation of the c-Met receptor and also inhibit HGF-independent activation of the human c-Met protein.Type: GrantFiled: November 3, 2011Date of Patent: January 28, 2014Assignee: arGEN-X B.V.Inventors: Anna Hultberg, Michael Saunders, Johannes De Haard, Els Festjens, Natalie De Jonge, Paolo Michieli, Cristina Basilico, Torsten Dreier
-
Publication number: 20130183690Abstract: Use of a polynucleotide encoding or a polypeptide comprising at least the extra-cellular IPT-3 and IPT-4 domains of hepatocyte growth factor receptor for the screening and/or development of pharmacologically active agents useful in the treatment of cancer, preferably a cancer with dysregulation of hepatocyte growth factor receptor.Type: ApplicationFiled: February 21, 2013Publication date: July 18, 2013Applicant: Metheresis Translational Research SAInventors: Paolo Maria COMOGLIO, Paolo Carminati, Paolo Michieli, Cristina Basilico
-
Patent number: 8404453Abstract: Use of a polynucleotide encoding or a polypeptide comprising at least the extracellular IPT-3 and IPT-4 domains of hepatocyte growth factor receptor for the screening and/or development of pharmacologically active agents useful in the treatment of cancer, preferably a cancer with dysregulation of hepatocyte growth factor receptor.Type: GrantFiled: May 13, 2009Date of Patent: March 26, 2013Assignee: Metheresis Translational Research SAInventors: Cristina Basilico, Paolo Michieli, Paolo Carminati, Paolo Maria Comoglio
-
Publication number: 20120156206Abstract: The invention provides a product combination or composition, and also multispecific antibodies comprising two or more antigen-binding sites (as antibodies or antigen binding fragments thereof), wherein two the antigen-binding bind to distinct non-overlapping epitopes of the human c-Met protein. The product combination or composition or multispecific antibody inhibits HGF-independent activation of the human c-Met receptor protein.Type: ApplicationFiled: November 3, 2011Publication date: June 21, 2012Applicant: ARGEN-X B.V.Inventors: Anna HULTBERG, Michael SAUNDERS, Johannes DE HAARD, Els FESTJENS, Nathalie DE JONGE, Paolo MICHIELI, Cristina Basilico, Torsten Dreier
-
Publication number: 20120148607Abstract: The present invention relates to antibodies that specifically bind to the human c-Met receptor protein and that act as strict antagonists of hepatocyte growth factor (HGF)-mediated activation of the c-Met receptor and also inhibit HGF-independent activation of the human c-Met protein.Type: ApplicationFiled: November 3, 2011Publication date: June 14, 2012Applicant: ARGEN-X B.V.Inventors: Anna HULTBERG, Michael SAUNDERS, Johannes DE HAARD, Els FESTJENS, Natalie DE JONGE, Paolo Michieli, Cristina Basilico, Torsten Dreier
-
Publication number: 20120115219Abstract: Use of a polynucleotide encoding or a polypeptide comprising at least the extra-cellular IPT-3 and IPT-4 domains of hepatocyte growth factor receptor for the screening and/or development of pharmacologically active agents useful in the treatment of cancer, preferably a cancer with dysregulation of hepatocyte growth factor receptor.Type: ApplicationFiled: August 31, 2011Publication date: May 10, 2012Applicant: Metheresis Translational Research SAInventors: Cristina Basilico, Paolo Michieli, Paolo Carminati, Paolo Maria Comoglio
-
Publication number: 20120108789Abstract: Use of a polynucleotide encoding or a polypeptide comprising at least the extra-cellular IPT-3 and IPT-4 domains of hepatocyte growth factor receptor for the screening and/or development of pharmacologically active agents useful in the treatment of cancer, preferably a cancer with dysregulation of hepatocyte growth factor receptor.Type: ApplicationFiled: August 31, 2011Publication date: May 3, 2012Applicant: Metheresis Translational Research SAInventors: Cristina Basilico, Paolo Michieli, Paolo Carminati, Paolo Maria Comoglio
-
Publication number: 20090298079Abstract: Use of a polynucleotide encoding or a polypeptide comprising at least the extracellular IPT-3 and IPT-4 domains of hepatocyte growth factor receptor for the screening and/or development of pharmacologically active agents useful in the treatment of cancer, preferably a cancer with dysregulation of hepatocyte growth factor receptor.Type: ApplicationFiled: May 13, 2009Publication date: December 3, 2009Applicant: Metheresis Translational Research SA,Inventors: Cristina Basilico, Paolo Michieli, Paolo Carminati, Paolo Maria COMOGLIO